{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:24:40Z","timestamp":1791401080786,"version":"4.3.3"},"reference-count":48,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The purpose of this study is to describe the clinical and prognostic features and to evaluate the outcome of different therapeutic approaches among patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who have been diagnosed and treated in different institutions. A total of 398 patients from 75 centers were included in the study. Treatment consisted of non-Hodgkin lymphoma (NHL)\u2013like regimens in 129 (32.8%) patients and acute leukemia (AL)\u2013like regimens in 113 (23.5%) patients. In 61 (15.5%) and 16 (4.1%) patients, chemotherapy was followed by allogeneic and autologous hematopoietic stem cell transplantation (HSCT), respectively. Twenty-seven (6.9%) patients received radiotherapy, 6 (1.5%) received new agents, and 62 (15.7%) received palliative care. After a median follow-up of 12 months, median overall survival (OS) was 18 months. Patients who received NHL\/AL-like regimens, followed by allogeneic HSCT, had the best outcome; median OS was not reached. OS was 65 months for patients who underwent autologous HSCT; 18 months and 14 months, respectively, for those treated with AL-like and NHL-like regimens without consolidation; and 4 months for those receiving palliative care (P &amp;lt; .001). In BPDCN, chemotherapy with lymphoma- or AL-like regimens, followed by transplantation, represents the therapeutic strategy associated with the best outcome. Consolidation with allogeneic HSCT, when feasible, appears superior to autologous HSCT.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002474","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T11:36:42Z","timestamp":1602070602000},"page":"4838-4848","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":90,"title":["Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients"],"prefix":"10.1182","volume":"4","author":[{"given":"Kamel","family":"Laribi","sequence":"first","affiliation":[{"name":"Department of Hematology, Centre Hospitalier Le Mans, Le Mans, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Baugier de Materre","sequence":"additional","affiliation":[{"name":"Geriatric Department, Assistance Publique\u2013H\u00f4pitaux de Paris, H\u00f4pital Broca, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Sobh","sequence":"additional","affiliation":[{"name":"Hematology, BMT Program, The Ottawa Hospital, Ottawa, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cerroni","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Graz, Graz, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina Giovanna","family":"Valentini","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli, IRCCS\u2013Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6782-8361","authenticated-orcid":false,"given":"Tomohiro","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5974-7614","authenticated-orcid":false,"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Oncology\/Hematology, Shimane University Hospital, Izumo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1599-5800","authenticated-orcid":false,"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Pathology Project for Molecular Targets and Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur E.","family":"Frankel","sequence":"additional","affiliation":[{"name":"University of South Alabama Mitchell Cancer Institute, Mobile, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Cota","sequence":"additional","affiliation":[{"name":"Department of Dermatology, IRCCS INRCA, Ancona, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ghez","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institut Gustave Roussy, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5883-1825","authenticated-orcid":false,"given":"Ronan","family":"Le Calloch","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne-Maladies du Sang-Maladies Infectieuses, Centre Hospitalier de Cornouaille, Quimper, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8287-928X","authenticated-orcid":false,"given":"Livio","family":"Pagano","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli, IRCCS\u2013Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Petrella","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Montr\u00e9al, Hospital Maisonneuve-Rosemont, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"2020100711361952200_B1","first-page":"146","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Facchetti","year":"2008","edition":"4th ed."},{"issue":"20","key":"2020100711361952200_B2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [published correction appears in Blood. 2016;128(3):462-463]","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2020100711361952200_B3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ajh.24258","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and HyperCVAD therapy","volume":"91","author":"Deotare","year":"2016","journal-title":"Am J Hematol"},{"issue":"22","key":"2020100711361952200_B4","doi-asserted-by":"crossref","first-page":"19204","DOI":"10.18632\/oncotarget.4146","article-title":"Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile","volume":"6","author":"Mart\u00edn-Mart\u00edn","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"2020100711361952200_B5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"2020100711361952200_B6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-018-0117-6","article-title":"Early detection of transformation to BPDCN in a patient with MDS","volume":"7","author":"Chamoun","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"2020100711361952200_B7","doi-asserted-by":"crossref","first-page":"Abstract 2723","DOI":"10.1182\/blood-2019-132185","article-title":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) commonly presents in the setting of prior or concomitant hematologic malignancies (PCHM): patient characteristics and outcomes in the rapidly evolving modern targeted therapy era [abstract]","volume":"134","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2020100711361952200_B8","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.bbmt.2013.01.027","article-title":"Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation","volume":"19","author":"Kharfan-Dabaja","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020100711361952200_B9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.leukres.2009.09.006","article-title":"Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group","volume":"34","author":"Tsagarakis","year":"2010","journal-title":"Leuk Res"},{"issue":"5","key":"2020100711361952200_B10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/PAS.0000000000000156","article-title":"Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients","volume":"38","author":"Julia","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2020100711361952200_B11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bjd.12412","article-title":"Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients","volume":"169","author":"Julia","year":"2013","journal-title":"Br J Dermatol"},{"issue":"3","key":"2020100711361952200_B12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","article-title":"Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"121","author":"Roos-Weil","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2020100711361952200_B13","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood-2015-01-621268","article-title":"Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm","volume":"125","author":"Aoki","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2020100711361952200_B14","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ccell.2016.10.002","article-title":"A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm","volume":"30","author":"Ceribelli","year":"2016","journal-title":"Cancer Cell"},{"issue":"10","key":"2020100711361952200_B15","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/PAS.0000000000001316","article-title":"Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm","volume":"43","author":"Sukswai","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"18","key":"2020100711361952200_B16","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"24","key":"2020100711361952200_B17","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia [published correction appears in J Clin Oncol. 2004;22(3):576]","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"27","key":"2020100711361952200_B18","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"17","key":"2020100711361952200_B19","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"2020100711361952200_B20","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1182\/blood.V99.11.4154","article-title":"CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique","volume":"99","author":"Leroux","year":"2002","journal-title":"Blood"},{"issue":"17","key":"2020100711361952200_B21","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1182\/blood-2011-03-337501","article-title":"Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion","volume":"118","author":"Lucioni","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2020100711361952200_B22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11864-019-0605-x","article-title":"Blastic plasmacytoid dendritic cell neoplasm","volume":"20","author":"Kerr","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"2020100711361952200_B23","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1309\/GJWNPD8HU5MAJ837","article-title":"Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review","volume":"123","author":"Petrella","year":"2005","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"2020100711361952200_B24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1586\/ehm.12.33","article-title":"Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care?","volume":"5","author":"Piccaluga","year":"2012","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"2020100711361952200_B25","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3109\/10428194.2012.656627","article-title":"Sequential combination of high dose methotrexate and L-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+\/CD56+ hematodermic neoplasm","volume":"53","author":"Gilis","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2020100711361952200_B26","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2019001144","article-title":"Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark","volume":"134","author":"Taylor","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2020100711361952200_B27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/bjh.12523","article-title":"L-asparaginase with methotrexate and dexamethasone is an effective treatment combination in blastic plasmacytoid dendritic cell neoplasm","volume":"163","author":"Gruson","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"2020100711361952200_B28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/1042819031000139648","article-title":"The treatment of acute lymphoblastic leukaemia in the elderly","volume":"45","author":"Pagano","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"2020100711361952200_B29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"2020100711361952200_B30","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2165\/00002512-200421120-00003","article-title":"Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches","volume":"21","author":"Robak","year":"2004","journal-title":"Drugs Aging"},{"issue":"2","key":"2020100711361952200_B31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-0609.2006.00778.x","article-title":"Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"78","author":"Sancho","year":"2007","journal-title":"Eur J Haematol"},{"issue":"2","key":"2020100711361952200_B32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.14146","article-title":"Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches","volume":"174","author":"Pagano","year":"2016","journal-title":"Br J Haematol"},{"key":"2020100711361952200_B33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.leukres.2018.08.014","article-title":"Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm","volume":"73","author":"Guru Murthy","year":"2018","journal-title":"Leuk Res"},{"issue":"3","key":"2020100711361952200_B34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.hoc.2020.01.002","article-title":"Molecular features of blastic plasmacytoid dendritic cell neoplasm: DNA mutations and epigenetics","volume":"34","author":"Sapienza","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"2020100711361952200_B35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2010.08556.x","article-title":"TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm","volume":"153","author":"Jardin","year":"2011","journal-title":"Br J Haematol"},{"issue":"4","key":"2020100711361952200_B36","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2006-04-018143","article-title":"Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities","volume":"109","author":"Dijkman","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2020100711361952200_B37","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/his.13340","article-title":"Clinicopathological analysis of 46 cases with CD4+ and\/or CD56+ immature haematolymphoid malignancy: reappraisal of blastic plasmacytoid dendritic cell and related neoplasms","volume":"71","author":"Suzuki","year":"2017","journal-title":"Histopathology"},{"issue":"12","key":"2020100711361952200_B38","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/modpathol.3800679","article-title":"Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms","volume":"19","author":"Jaye","year":"2006","journal-title":"Mod Pathol"},{"issue":"7","key":"2020100711361952200_B39","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/annonc\/mdh268","article-title":"CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature","volume":"15","author":"Bekkenk","year":"2004","journal-title":"Ann Oncol"},{"issue":"5","key":"2020100711361952200_B40","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/cncr.21268","article-title":"Blastic natural killer cell lymphoma\/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement","volume":"104","author":"Suzuki","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"2020100711361952200_B41","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"Frankel","year":"2014","journal-title":"Blood"},{"key":"2020100711361952200_B42","doi-asserted-by":"crossref","first-page":"Abstract 811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial [abstract]","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020100711361952200_B43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2020100711361952200_B44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"2020100711361952200_B45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov"},{"key":"2020100711361952200_B46","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMc1814963","article-title":"More on blastic plasmacytoid dendritic-cell neoplasms","volume":"380","author":"Micol","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"2020100711361952200_B47","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMc1808354","article-title":"Venetoclax in a patient with a blastic plasmacytoid dendritic-cell neoplasm","volume":"379","author":"Agha","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2020100711361952200_B48","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMc1814963","article-title":"More on blastic plasmacytoid dendritic-cell neoplasms","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/19\/4838\/1760587\/advancesadv2020002474.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/19\/4838\/1760587\/advancesadv2020002474.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T06:37:22Z","timestamp":1698215842000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/19\/4838\/464090\/Blastic-plasmacytoid-dendritic-cell-neoplasms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":48,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002474","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]}}}